Birdsall M, Pattison N, Chamley L
Department of Obstetrics and Gynaecology, National Women's Hospital, Auckland, New Zealand.
Aust N Z J Obstet Gynaecol. 1992 Nov;32(4):328-30. doi: 10.1111/j.1479-828x.1992.tb02844.x.
We assessed the relationship between antiphospholipid antibodies and recurrent miscarriage, fetal deaths, and the pregnancy complications--placental abruption, fetal growth retardation and preeclampsia. The subjects were 81 women with a history of 3 or more miscarriages, 62 with a history of fetal death in the index pregnancy, 105 with a poor obstetric history or pregnancy complications and 13 with systemic lupus erythematosus. Antiphospholipid antibodies were found in 41% of women with a history of recurrent miscarriages, 29% with a history of recent intermediate fetal death or stillbirth, 19% with a poor obstetric history and 69% with systemic lupus erythematosus. There is a high incidence of antiphospholipid antibodies in complicated pregnancies. Patients presenting with the above pregnancy disorders should be tested for antiphospholipid antibodies because of the risk conferred on a fetus by their presence and to expand the treatment options.
我们评估了抗磷脂抗体与复发性流产、胎儿死亡以及妊娠并发症（胎盘早剥、胎儿生长受限和先兆子痫）之间的关系。研究对象包括81名有3次或更多次流产史的女性、62名在本次妊娠中有胎儿死亡史的女性、105名有不良产科病史或妊娠并发症的女性以及13名系统性红斑狼疮患者。在有复发性流产史的女性中，41%检测出抗磷脂抗体；在近期有中期胎儿死亡或死产史的女性中，29%检测出抗磷脂抗体；在有不良产科病史的女性中，19%检测出抗磷脂抗体；在系统性红斑狼疮患者中，69%检测出抗磷脂抗体。在复杂妊娠中，抗磷脂抗体的发生率很高。由于抗磷脂抗体的存在会给胎儿带来风险，并为了扩大治疗选择，出现上述妊娠疾病的患者应检测抗磷脂抗体。
